Tagged Articles

pioglitazone 56 articles

Diabetes drug Actos linked to weight gain

Obesity is a risk factor for type 2 diabetes and most patients who suffer from the condition are encouraged to lose weight. However, a type of commonly used diabetes drugs can actually increase body fat in people, according to new research published in The Journal of Neuroscience. The body fat increase was associated with a class of type 2 diabetes drugs known as thiazolidinediones, or TZDs. Drugs in this class include Actos (pioglitazone), Actoplus Met (pioglitazone and metformin), Duetact (pioglitazone and glimepride), Avandia (rosiglitazone), Avandamet (rosiglitazone and metformin), and Avandaryl (rosiglitazone and glimepride). The medical community has known for a ... Read More

Using type 2 diabetes drug Actos a risk factor for bladder cancer

The American Cancer Society warns that long-term use of the type 2 diabetes drug Actos, known generically as pioglitazone, can increase the risk of bladder cancer. The bladder is a hollow organ in the pelvis with flexible, muscular walls designed to store urine before it leaves the body. There are four main layers to the bladder. The innermost lining is made up of cells called urothelial or transitional cells. The next layer, called the urothelium, is made of up a thin layer of connective tissue, blood vessels, and nerves. Next is a layer of muscle, and the outer layer is ... Read More

Short-term use, lower doses of Actos linked to increased bladder cancer risk

People who have been treated with the type 2 diabetes medication Actos (pioglitazone) for more than six months may be at greater risk of developing bladder cancer, even if they were on a low dose, according to a new study published in the Journal of Korean Medical Science and reported by Cancer Monthly. In 2011, studies showed long-term use (12 months or greater) of Actos increased the risk for bladder cancer. As a result, some countries banned the drug. The U.S. Food and Drug Administration (FDA) ordered that Actos and its generic equivalents include a warning on their safety labels ... Read More

Top selling type 2 diabetes drugs carry cancer risks

Januvia was the top selling diabetes drug in the country for the 12 months ending September 2013, according to IMS Health. Januvia earned $2.8 billion during that period with more than 8.7 million in prescriptions, giving it an overall ranking of 14th on the list of top 100 prescription drug sales. Sitagliptin is the active ingredient in Januvia. It is also used in combination with metformin in the type 2 diabetes medication Janumet. That drug ranks 47th on the list of top selling pharmaceuticals with $967 million in sales and 3.26 million prescriptions. Actos, which contains the medication pioglitazone, ranks ... Read More

Actos label updated to advise against use in pediatric patients with type 2 diabetes

The type 2 diabetes drug Actos is not recommended for children or adolescents because of potentially dangerous side effects including fluid retention and congestive heart failure, fractures and urinary bladder tumors, according to an update to the drug’s safety label. Actos, known generically as pioglitazone, is an oral diabetes medicine that helps control blood sugar levels. It is approved for use in adults with type 2 diabetes, a chronic condition often associated with obesity and a sedentary lifestyle. The condition was once known as “adult onset diabetes,” however, with increasing childhood obesity, more children and adolescents are being diagnosed with ... Read More

Studies look at cancer risk, prevention with type 2 diabetes medications

A type of diabetes medications known as insulin sensitizers may reduce the risk of cancer by a third in women who used the drugs, a new study suggests. Insulin sensitizers include the commonly prescribed drug metformin as well as Avandia, known generically as rosiglitazone, and Actos, known generically as pioglitazone. The new study claims these insulin sensitizers were better at preventing cancer in women than diabetes drugs known as insulin secretagogues such as glyburide, glipizide and glimepiride. Type 2 diabetics are already 30 to 50 times more likely to develop cancer than those without the metabolic disorder. Women with diabetes ... Read More

Diabetes drugs may not increase heart problems but could pose cancer risk

Studies involving different type 2 diabetes drugs show no evidence that the medications cause heart attacks and strokes, however they do not improve cardiovascular outcomes in patients either. Some medications also pose cancer risks. The first study compared the drug saxagliptin, marketed in the United States as Onglyza, with a placebo in patients who had type 2 diabetes and were considered at high risk for a cardiovascular event. Another study pitted the drug alogliptin, marketed as Nesina, against placebo. Researchers recorded incidences of cardiovascular death, heart attack or ischemic stroke as well as hospitalizations for unstable angina, coronary revascularization or ... Read More

UK drug regulators close to approving risky type 2 diabetes treatments

European drug authorities are close to approving new treatments for type 2 diabetes. The European Medicines Agency (EMA) issued a favorable opinion for Takeda Pharmaceuticals drug alogliptin as a stand-alone drug, in combination with metformin, and in combination with pioglitazone. The drugs will be sold under the brand names Vipidia, Incresync, and Vipdomet, respectively. The three drugs were launched last month in the United States under the brand names Nesina, Oseni and Kazano. Alogliptin is in a class of medications known as dipeptidyl peptidase 4 (DPP-4) inhibitors. They work by slowing the inactivation of the incretin hormones that regulate blood ... Read More

Indian government bans sale of Actos diabetes drug

Indian drug regulators have suspended sales of the type 2 diabetes drug pioglitazone (known in the United States as Actos), as well as two other drugs – analgin and deanxit – without specifying a reason. Drug companies that market the diabetes drug are taking aim at India’s Drug Technical Advisory Board (DTAB) for the action. “We are demanding a review,” said Indian Pharmaceutical Alliance secretary general D. G. Shah. “A ban has to be based on science and scientific data. It has to follow a proper process and be evaluated by the DTAB and with the knowledge and consultation of ... Read More

Nearly 25,000 adverse events associated with diabetes drug Actos

More than 24,000 adverse events have been reported to the Food and Drug Administration (FDA) regarding the type 2 diabetes drug Actos since the medication was introduced nearly 14 years ago. The most commonly reported side effect in which Actos is the primary culprit is bladder cancer. Other, less commonly reported side effects reported with Actos include weight gain, fluid retention, congestive heart failure, heart failure, and abnormal liver function. Actos is a medication used to control blood glucose levels in adults with type 2 diabetes. It is manufactured by Japanese drug company Takeda Pharmaceuticals. In 2011, the FDA issued ... Read More